Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53

Proteomics - Clinical Applications

Volumn 6, Issue 5-6, 2012, Pages 279-290

  Almazi, Juhura G ^a   Mactier, Swetlana ^a   Best, O Giles ^b   Crossett, Ben ^a   Mulligan, Stephen P ^b   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

B lymphoproliferative disorders; Fludarabine; P53; P63; P73

Indexed keywords

FLUDARABINE; MESSENGER RNA; PROTEIN P53; PROTEIN P63; PROTEIN P73;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; ELECTROPHORESIS; HUMAN; HUMAN CELL; LYMPHOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; MITOCHONDRION; MOLECULAR WEIGHT; ONE DIMENSIONAL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOSOL; DNA-BINDING PROTEINS; HUMANS; MEMBRANE PROTEINS; NUCLEAR PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIDARABINE;

EID: 84863228976     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200003     Document Type: Article

References (58)

1. Anderson, K. C., Barlogie, B., Bloomfield, C., Dalla-Favera, R. et al., Report of the leukemia, lymphoma and myeloma: National Cancer Institute, Bethesda, MD, 2001, .
2. Tsutsumi, Y., Kanamori, H., Minami, H., Musashi, M. et al., Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine. Ann. Hematol. 2005, 84, 269-271.
3. Henrich, S., Gez, S., Crossett, B., Mulligan, S. P. et al., Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleo. Nucleot. Nucleic Acids 2008, 27, 634-640.
4. Appella, E., Anderson, C. W., Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 2001, 268, 2764-2772.
5. Prives, C., Hall, P. A., The p53 pathway. J. Pathol. 1999, 187, 112-126.
6. Appella, E., Anderson, C. W., Signaling to p53: breaking the posttranslational modification code. Pathol. Biol. (Paris) 2000, 48, 227-245.
7. El-Deiry, W. S. S. C. B. Regulation of p53 downstream genes. Semin. Cancer Biol. 1998, 8, 345-357.
8. Zhao, R., Gish, K., Murphy, M., Yin, Y. et al., Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 2000, 14, 981-993.
9. Smith, M. L., Ford, J. M., Hollander, M. C., Bortnick, R. A. et al., p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol. Cell. Biol. 2000, 20, 3705-3714.
10. Dasika, G. K., Lin, S. C., Zhao, S., Sung, P. et al., DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 1999, 18, 7883-7899.
11. Oren, M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10, 431-442.
12. Miyashita, T., Reed, J. C., Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80, 293-299.
13. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S. et al., Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 1995, 15, 3032-3040.
14. Sansome, C., Zaika, A., Marchenko, N. D., Moll, U. M., Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett. 2001, 488, 110-115.
15. Marchenko, N. D., Zaika, A., Moll, U. M., Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 2000, 275, 16202-16212.
16. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E. et al., Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell. Biol. 2004, 6, 443-450.
17. Jiang, P., Du, W., Heese, K., Wu, M., The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol. Cell. Biol. 2006, 26, 9071-9082.
18. Chipuk, J. E., Maurer, U., Green, D. R., Schuler, M., Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003, 4, 371-381.
19. Achanta, G., Sasaki, R., Feng, L., Carew, J. S. et al., Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005, 24, 3482-3492.
20. de Souza-Pinto, N. C., Harris, C. C., Bohr, V. A., p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria. Oncogene 2004, 23, 6559-6568.
21. Henrich, S., Christopherson, R. I., Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine. Leukemia 2008, 22, 657-660.
22. Sadji-Ouatas, Z., Lasfer, M., Julien, S., Feldmann, G. et al., Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines. Biochemistry 2002, 364, 881-885.
23. Sayan, B. S., Sayan, A. E., Knight, R. A., Melino, G. et al., p53 is cleaved by caspases generating fragments localizing to mitochondria. J. Biol. Chem. 2006, 281, 13566-13573.
24. Marin, M. C., Kaelin, W. G. J., p63 and p73: old members of a new family. Biochim. Biophys. Acta 2000, 18, M93-M100.
25. Petitjean, A., Ruptier, C., Tribollet, V., Hautefeuille, A. et al., Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73. Carcinogenesis 2008, 29, 273-281.
26. Levrero, M., De Laurenzi, V., Costanzo, A., Gong, J. et al., The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell. Sci. 2000, 113(PART 10), 1661-1670.
27. Müller, M., Schleithoff, E. S., Stremmel, W., Melino, G. et al., One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist. Updates 2006, 9, 288--306.
28. Yang, A., Kaghad, M., Wang, Y., Gillett, E. et al., p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 1998, 2, 305-316.
29. McKeon, F., p63 and the epithelial stem cell: more than status quo? Genes Dev. 2004, 18, 465-469.
30. Mills, A. A. p63: oncogene or tumor suppressor? Curr. Opin. Genet Dev. 2006, 16, 38-44.
31. Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J. et al., Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005, 7, 363-373.
32. Keyes, W. M., Wu, Y., Vogel, H., Guo, X. et al., p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 2005, 19, 1986-1999.
33. Keyes, W. M., Vogel, H., Koster, M. I., Guo, X. et al., p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc. Natl. Acad. Sci. USA 2006, 103, 8435-8440.
34. Murray-Zmijewski, F., Lane, D. P., Bourdon, J. C., p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006, 13, 962-972.
35. Irwin, M. S., Miller, F. D. p73: regulator in cancer and neural development. Cell Death Differ. 2004, 11, S17-S22.
36. Fillippovich, I., Sorokina, N., Gatei, M., Haupt, Y. et al., Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 2001, 20, 514-522.
37. Rosenwald, A., Chuang, E. Y., Davis, R. E., Wiestner, A. et al., Fludarabine treatment of chronic lymphocytic leukemia patients induces a p53-dependent gene expression response. Blood 2004, 18, 1428-1434.
38. Gez, S., Crossett, B., Christopherson, R. I. Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. Biochim. Biophys. Acta 2007, 1774, 1173-1183.
39. Arnoult, D., Karbowski, M., Youle, R. J., Caspase inhibition prevents the mitochondrial release of apoptosis-inducing factor. Cell Death Differ. 2003, 10, 845-849.
40. Mactier, S., Henrich, S., Che, Y., Kohnke, P. L. et al., Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma. J. Proteome Res. 2011, 10, 1030-1042.
41. Chipuk, J. E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D. D. et al., PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005, 309, 1732-1735.
42. Stacchini, A., Aragno, M., Vallario, A., Alfarano, A. et al., MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leukemia Res. 1999, 23, 127-136.
43. Moll, U. M., Petrenko, O., The MDM2-p53 interaction. Mol. Cancer Res. 2003, 1, 1001-1008.
44. Nakagawa, K., Taya, Y., Tamai, K., Yamaizumi, M., Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks. Mol. Cell. Biol. 1999, 19, 2828-2834.
45. Sakaguchi, K., Sakamoto, H., Lewis, M. S., Anderson, C. W. et al., Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 1997, 36, 10117-10124.
46. Sadji-Ouatas, Z., Lasfer, M., Julien, S., Feldmann, G. et al., Doxorubicin and octreotide induce a 40 kDa breakdown product of p53 in human hepatoma and tumoral colon cell lines. Biochem. J. 2002, 364, 881-885.
47. Okorokov, A. L., Ponchel, F., Milner, J., Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNAinduces C-terminal cleavage of p53. EMBO J. 1997, 16, 6008-6017.
48. Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., Liu, G. et al., p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005, 19, 2122-2137.
49. Rohaly, G., Chemnitz, J., Dehde, S., Nunez, A. M. et al., A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005, 122, 21-32.
50. Flores, E. R., Tsai, K. Y., Crowley, D., Sengupta, S. et al., p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416, 560-564.
51. Demczuk, S., Harbers, M., Vennstrom, B., Identification and analysis of all components of a gel retardation assay by combination with immunoblotting. Proc. Natl. Acad. Sci. USA 1993, 90, 2574-2578.
52. Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E. et al., TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005, 24, 2458-2471.
53. Pruneri, G., Fabris, S., Dell'Orto, P., Biasi, M. O. et al., The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J. Pathol. 2005, 206, 337-345.
54. Sayan, B. S., Sayan, A. E., Yang, A. L., Aqeilan, R. I. et al., Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proc. Natl. Acad. Sci. USA 2007, 104, 10871-10876.
55. Zhu, J., Nozell, S., Wang, J., Jiang, J. et al., p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene 2001, 20, 4050-4057.
56. Cabrera-Socorro, A., Hernandez-Acosta, N. C., Gonzalez-Gomez, M., Meyer, G., Comparative aspects of p73 and Reelin expression in Cajal-Retzius cells and the cortical hem in lizard, mouse and human. Brain Res. 2007, 1132, 59-70.
57. Sayan, A. E., Sayan, B. S., Gogvadze, V., Dinsdale, D. et al., p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene 2008, 27, 4363-4372.
58. Zaika, A. I., Kovalev, S., Marchenko, N. D., Moll, U. M., Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 1999, 59, 3257-3263.